Literature DB >> 21149621

FKS2 mutations associated with decreased echinocandin susceptibility of Candida glabrata following anidulafungin therapy.

Sofia Costa-de-Oliveira1, Isabel Marcos Miranda, Raquel M Silva, Ana Pinto E Silva, Rita Rocha, António Amorim, Acácio Gonçalves Rodrigues, Cidália Pina-Vaz.   

Abstract

This is the first case report of Candida glabrata-disseminated candidiasis describing the acquisition of echinocandin resistance following anidulafungin treatment. The initial isolates recovered were susceptible to echinocandins. However, during 27 days of anidulafungin treatment, two resistant strains were isolated (from the blood and peritoneal fluid). The resistant peritoneal fluid isolate exhibited a Ser663Pro mutation in position 1987 of FKS2 HS1 (hot spot 1), whereas the resistant blood isolate displayed a phenylalanine deletion (Phe659).

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 21149621      PMCID： PMC3067100          DOI： 10.1128/AAC.00589-10

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  24 in total

1.  Escape of Candida from caspofungin inhibition at concentrations above the MIC (paradoxical effect) accomplished by increased cell wall chitin; evidence for beta-1,6-glucan synthesis inhibition by caspofungin.

Authors:  David A Stevens; Masayuki Ichinomiya; Yukako Koshi; Hiroyuki Horiuchi
Journal:  Antimicrob Agents Chemother       Date:  2006-09       Impact factor: 5.191

2.  Assessing resistance to the echinocandin antifungal drug caspofungin in Candida albicans by profiling mutations in FKS1.

Authors:  Sergey V Balashov; Steven Park; David S Perlin
Journal:  Antimicrob Agents Chemother       Date:  2006-06       Impact factor: 5.191

3.  Candida albicans and Candida glabrata clinical isolates exhibiting reduced echinocandin susceptibility.

Authors:  Santosh Katiyar; Michael Pfaller; Thomas Edlind
Journal:  Antimicrob Agents Chemother       Date:  2006-08       Impact factor: 5.191

4.  Novel FKS mutations associated with echinocandin resistance in Candida species.

Authors:  Guillermo Garcia-Effron; Daniel Joseph Chua; Jon Rupert Tomada; Joseph DiPersio; David S Perlin; Mahmoud Ghannoum; Hector Bonilla
Journal:  Antimicrob Agents Chemother       Date:  2010-02-09       Impact factor: 5.191

5.  Low prevalence of fks1 hot spot 1 mutations in a worldwide collection of Candida strains.

Authors:  Mariana Castanheira; Leah N Woosley; Daniel J Diekema; Shawn A Messer; Ronald N Jones; Michael A Pfaller
Journal:  Antimicrob Agents Chemother       Date:  2010-04-05       Impact factor: 5.191

6.  A naturally occurring proline-to-alanine amino acid change in Fks1p in Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis accounts for reduced echinocandin susceptibility.

Authors:  Guillermo Garcia-Effron; Santosh K Katiyar; Steven Park; Thomas D Edlind; David S Perlin
Journal:  Antimicrob Agents Chemother       Date:  2008-04-28       Impact factor: 5.191

7.  The changing epidemiology of invasive candidiasis: Candida glabrata and Candida krusei as the leading causes of candidemia in hematologic malignancy.

Authors:  Ray Hachem; Hend Hanna; Dimitrios Kontoyiannis; Ying Jiang; Issam Raad
Journal:  Cancer       Date:  2008-06       Impact factor: 6.860

8.  Progressive loss of echinocandin activity following prolonged use for treatment of Candida albicans oesophagitis.

Authors:  Michel Laverdière; Richard G Lalonde; Jean-Guy Baril; Donald C Sheppard; Steven Park; David S Perlin
Journal:  J Antimicrob Chemother       Date:  2006-02-07       Impact factor: 5.790

9.  Effect of Candida glabrata FKS1 and FKS2 mutations on echinocandin sensitivity and kinetics of 1,3-beta-D-glucan synthase: implication for the existing susceptibility breakpoint.

Authors:  Guillermo Garcia-Effron; Samuel Lee; Steven Park; John D Cleary; David S Perlin
Journal:  Antimicrob Agents Chemother       Date:  2009-06-22       Impact factor: 5.191

10.  Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America.

Authors:  Peter G Pappas; Carol A Kauffman; David Andes; Daniel K Benjamin; Thierry F Calandra; John E Edwards; Scott G Filler; John F Fisher; Bart-Jan Kullberg; Luis Ostrosky-Zeichner; Annette C Reboli; John H Rex; Thomas J Walsh; Jack D Sobel
Journal:  Clin Infect Dis       Date:  2009-03-01       Impact factor: 9.079
View more
  14 in total

1.  Frequency of decreased susceptibility and resistance to echinocandins among fluconazole-resistant bloodstream isolates of Candida glabrata.

Authors:  M A Pfaller; M Castanheira; S R Lockhart; A M Ahlquist; S A Messer; R N Jones
Journal:  J Clin Microbiol       Date:  2012-01-25       Impact factor: 5.948

2.  Stepwise development of a homozygous S80P substitution in Fks1p, conferring echinocandin resistance in Candida tropicalis.

Authors:  Rasmus Hare Jensen; Helle Krogh Johansen; Maiken Cavling Arendrup
Journal:  Antimicrob Agents Chemother       Date:  2012-10-22       Impact factor: 5.191

3.  Recurrent episodes of candidemia due to Candida glabrata with a mutation in hot spot 1 of the FKS2 gene developed after prolonged therapy with caspofungin.

Authors:  María Teresa Durán-Valle; Sara Gago; Alicia Gómez-López; Manuel Cuenca-Estrella; Leticia Jiménez Díez-Canseco; José Luis Gómez-Garcés; Oscar Zaragoza
Journal:  Antimicrob Agents Chemother       Date:  2012-03-05       Impact factor: 5.191

4.  Activity of Combined Antifungal Agents Against Multidrug-Resistant Candida glabrata Strains.

Authors:  Laura Bedin Denardi; Jéssica Tairine Keller; Vanessa Oliveira; Débora Alves Nunes Mario; Janio Morais Santurio; Sydney Hartz Alves
Journal:  Mycopathologia       Date:  2017-05-10       Impact factor: 2.574

5.  Target enzyme mutations confer differential echinocandin susceptibilities in Candida kefyr.

Authors:  Janet F Staab; Dionysios Neofytos; Peter Rhee; Cristina Jiménez-Ortigosa; Sean X Zhang; David S Perlin; Kieren A Marr
Journal:  Antimicrob Agents Chemother       Date:  2014-06-30       Impact factor: 5.191

6.  Genetic Basis of Azole and Echinocandin Resistance in Clinical Candida glabrata in Japan.

Authors:  Hazim O Khalifa; Teppei Arai; Hidetaka Majima; Akira Watanabe; Katsuhiko Kamei
Journal:  Antimicrob Agents Chemother       Date:  2020-08-20       Impact factor: 5.191

7.  The presence of an FKS mutation rather than MIC is an independent risk factor for failure of echinocandin therapy among patients with invasive candidiasis due to Candida glabrata.

Authors:  Ryan K Shields; M Hong Nguyen; Ellen G Press; Andrea L Kwa; Shaoji Cheng; Chen Du; Cornelius J Clancy
Journal:  Antimicrob Agents Chemother       Date:  2012-07-02       Impact factor: 5.191

8.  Breakthrough candidemia due to multidrug-resistant Candida glabrata during prophylaxis with a low dose of micafungin.

Authors:  Fernando César Bizerra; Cristina Jimenez-Ortigosa; Ana Carolina R Souza; Giovanni Luis Breda; Flávio Queiroz-Telles; David S Perlin; Arnaldo L Colombo
Journal:  Antimicrob Agents Chemother       Date:  2014-01-27       Impact factor: 5.191

9.  Optimizing Echinocandin dosing and susceptibility breakpoint determination via in vivo pharmacodynamic evaluation against Candida glabrata with and without fks mutations.

Authors:  Alexander Lepak; Mariana Castanheira; Daniel Diekema; Michael Pfaller; David Andes
Journal:  Antimicrob Agents Chemother       Date:  2012-09-04       Impact factor: 5.191

10.  Evaluation of caspofungin susceptibility testing by the new Vitek 2 AST-YS06 yeast card using a unique collection of FKS wild-type and hot spot mutant isolates, including the five most common candida species.

Authors:  Karen M Astvad; David S Perlin; Helle K Johansen; Rasmus H Jensen; Maiken C Arendrup
Journal:  Antimicrob Agents Chemother       Date:  2012-10-22       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.